Contract drug manufacturing (CDMO) stocks
CDMO
What are Contract drug manufacturing (CDMO) stocks in Korea?
The Contract drug manufacturing (CDMO) theme on jonbur groups 32 Korean stocks listed on KOSPI and KOSDAQ, worth ₩160T in total. On Oct 26, 2026 the group moved down 1.98% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Alteogen.
Key facts
- Stocks
- 32
- Total market value
- ₩160T
- Day's move
- −1.98%
- As of
- Oct 26, 2026
- Largest members
- Samsung Biologics, Celltrion, Alteogen
Earnings tracker · 2Q 2026
Past quarter
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Samsung Biologics | Aug 14 | ₩1.3T | +2.4% | ₩586B | +23.3% | +1.0% | 44.4%36.9% |
| Celltrion | Aug 14 | ₩1.4T | +45.0% | ₩452B | +86.3% | +40.4% | 32.4%25.2% |
| Alteogen | Aug 7 | ₩69B | +269.5% | ₩34B | Turned to profit | −13.0% | 49.6%−2.3% |
| Yuhan | Aug 14 | ₩639B | +10.4% | ₩67B | +34.1% | +658.6% | 10.5%8.6% |
| HLB | Aug 14 | ₩28B | +78.0% | −₩23B | Smaller loss | Smaller loss | −80.4%−146.6% |
| Hanmi Pharm | Aug 14 | ₩467B | +29.3% | ₩131B | +116.9% | +144.4% | 28.1%16.7% |
| SAM Chun Dang Pharm | Aug 14 | ₩71B | +24.3% | ₩3.4B | Turned to profit | −36.9% | 4.9%−1.9% |
| Hanall Biopharma | Aug 14 | ₩44B | +8.8% | ₩5.6B | +388.5% | +567.4% | 12.6%2.8% |
| D&D Pharmatech | Aug 14 | ₩662M | −28.4% | −₩9.9B | Bigger loss | Smaller loss | −1,492.3%−871.7% |
| ST Pharm | Aug 14 | ₩108B | +58.9% | ₩18B | +41.7% | +58.8% | 16.9%18.9% |
| GC Biopharma | Aug 14 | ₩421B | −15.8% | ₩1.7B | −93.7% | −85.3% | 0.4%5.5% |
| Daewoong Pharma | Aug 14 | ₩448B | +10.6% | ₩68B | +17.7% | +206.5% | 15.2%14.3% |
| Chong Kun Dang Pharmaceutical | Aug 14 | ₩478B | +10.0% | ₩19B | −21.3% | +32.1% | 3.9%5.4% |
| Proteina | Aug 14 | ₩349M | — | −₩4B | — | Smaller loss | −1,132.6% |
| Shinpoong Pharmaceutical | Aug 14 | ₩64B | +9.0% | −₩8B | Turned to loss | Bigger loss | −12.6%8.4% |
| Samyang Holdings | Aug 14 | ₩963B | +6.1% | ₩61B | +40.4% | +107.6% | 6.3%4.7% |
| IL Dong Pharmaceutical | Jul 30 | ₩148B | +6.8% | ₩2B | +232.1% | −78.5% | 1.3%0.4% |
| Dong-A ST | Aug 14 | ₩225B | +15.8% | ₩6.3B | Turned to profit | −18.9% | 2.8%−3.0% |
| Inventage Lab | Aug 26 | ₩176M | −79.7% | −₩10B | Bigger loss | Bigger loss | −5,851.5%−930.7% |
| ToolGen | Aug 14 | ₩487M | +241.6% | −₩6.9B | Bigger loss | Bigger loss | −1,414.5%−4,439.8% |
| IMBiologics | Aug 12 | ₩0 | — | −₩2.7B | — | Turned to loss | — |
| Binex | Aug 14 | ₩38B | −15.1% | −₩9.2B | Turned to loss | Bigger loss | −24.2%2.3% |
| Huons | Aug 14 | ₩147B | −5.8% | ₩2.9B | −77.6% | Turned to profit | 2.0%8.4% |
| BNC Korea | Aug 14 | ₩25B | −0.1% | −₩366M | Turned to loss | Smaller loss | −1.5%6.5% |
| Kolon Life Science | Aug 14 | ₩51B | −4.5% | −₩785M | Turned to loss | Turned to loss | −1.6%2.4% |
| Aptabio Therapeutics | Aug 14 | ₩1.6B | +42.8% | −₩3.6B | Smaller loss | Smaller loss | −223.0%−368.5% |
| Dongsung Pharmaceutical | Aug 14 | ₩22B | +10.6% | −₩2B | Smaller loss | Turned to loss | −9.2%−20.8% |
| ilShinbiobase | — | ₩4.2B | +17.8% | ₩1.5B | +36.2% | +235.8% | 36.6%31.6% |
| Aprogen Biologics | Aug 13 | ₩23B | +54.9% | −₩17B | Smaller loss | Bigger loss | −75.7%−120.5% |
| SeouLin Bioscience | Aug 13 | ₩21B | +28.2% | −₩597M | Bigger loss | Turned to loss | −2.9%−2.0% |
| Dt&Cro | Aug 14 | ₩11B | +12.3% | −₩6.6B | Bigger loss | Bigger loss | −58.1%−19.6% |
| C&R Research | Aug 14 | ₩18B | +5.0% | ₩176M | −86.0% | Turned to profit | 1.0%7.4% |
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 26, 2026- Above 20-day average
- 18.8%
- Above 60-day average
- 25%
- RSI above 70
- 0%
- RSI below 30
- 18.8%
- 52-week highs
- 0
- 52-week lows
- 6
Index gauge · Short term
Bearish
0 bullish, 2 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The contract drug manufacturing (CDMO) theme covers 32 member stocks, and the technical picture is weak, with only 18.8% trading above their 20-day averages and 25% above their 60-day averages. None of the members hit a 52-week high, while 6 touched a 52-week low, and the lowest RSI reading was 18.8 with no member showing an elevated RSI. The equal-weighted member index shows bearish readings on both short- and medium-term signals, with an RSI of 38.1 and the index trading below its cloud.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
- MaturitiesOct 23, 202685GC Biopharma: ₩130bn of bonds due in the next 6 months vs ₩42bn cash₩130bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.GC Biopharma
Contract drug manufacturing (CDMO)
−2.37%CDMO
The CDMO (contract development and manufacturing organization) theme covers Korean companies that develop and manufacture pharmaceuticals, biologics, and related products on behalf of other drug companies, rather than selling their own branded medicines. Korean investors often group these firms together because they share a business model centered on large-scale bioproduction capacity, long-term client contracts, and exposure to the global biopharma outsourcing trend. The theme is also frequently linked to the broader Korean biotech sector, so its share prices tend to move alongside related names.
32 companies · 3 up · 0 flat · 29 down
- Traded value
- ₩293B
- Value vs 20-day average
- 0.56×
- Top gainer
- Proteina +7.25%
- Largest company
- Samsung Biologics ₩67T
Companies in this theme
| Company | Price | Daily | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,452,000 | −0.95% | ₩50B | ₩67T | 6.88% |
Celltrion068270 · KOSPI | ₩190,000 | −2.26% | ₩82B | ₩44T | 7.28% |
Alteogen196170 · KOSDAQ | ₩218,500 | −2.67% | ₩36B | ₩15T | 2.68% |
Yuhan000100 · KOSPI | ₩81,700 | −3.54% | ₩14B | ₩6T | 6.83% |
HLB028300 · KOSDAQ | ₩39,250 | −5.65% | ₩18B | ₩5.2T | 1.16% |
Hanmi Pharm128940 · KOSPI | ₩352,500 | −2.49% | ₩24B | ₩4.5T | 9.61% |
SAM Chun Dang Pharm000250 · KOSDAQ | ₩188,900 | −5.17% | ₩17B | ₩4.4T | 1.34% |
Hanall Biopharma009420 · KOSPI | ₩38,550 | −4.10% | ₩5.3B | ₩2T | 10.56% |
D&D Pharmatech347850 · KOSDAQ | ₩40,650 | −0.25% | ₩13B | ₩1.9T | 1.75% |
ST Pharm237690 · KOSDAQ | ₩88,500 | −1.56% | ₩4B | ₩1.8T | 5.77% |
GC Biopharma006280 · KOSPI | ₩129,600 | −1.97% | ₩1.7B | ₩1.5T | 6.68% |
Daewoong Pharma069620 · KOSPI | ₩100,600 | −1.76% | ₩1.7B | ₩1.2T | 10.30% |
Chong Kun Dang Pharmaceutical185750 · KOSPI | ₩61,900 | −4.33% | ₩999M | ₩854B | 6.34% |
Proteina468530 · KOSDAQ | ₩46,600 | +7.25% | ₩15B | ₩517B | 3.78% |
Shinpoong Pharmaceutical019170 · KOSPI | ₩8,250 | −4.84% | ₩1.6B | ₩432B | 0.39% |
Samyang Holdings000070 · KOSPI | ₩51,600 | −1.90% | ₩450M | ₩401B | 2.68% |
IL Dong Pharmaceutical249420 · KOSPI | ₩12,400 | −2.97% | ₩853M | ₩392B | 2.30% |
Dong-A ST170900 · KOSPI | ₩33,900 | −2.02% | ₩297M | ₩330B | 4.78% |
Inventage Lab389470 · KOSDAQ | ₩22,850 | −6.16% | ₩1.1B | ₩304B | 0.31% |
ToolGen199800 · KOSDAQ | ₩27,850 | −0.18% | ₩182M | ₩272B | 0.43% |
IMBiologics493280 · KOSDAQ | ₩14,180 | −2.41% | ₩723M | ₩211B | — |
Binex053030 · KOSDAQ | ₩6,210 | +0.49% | ₩2B | ₩203B | 2.17% |
Huons243070 · KOSDAQ | ₩16,850 | −2.99% | ₩515M | ₩202B | 0.71% |
BNC Korea256840 · KOSDAQ | ₩2,475 | −3.32% | ₩1.5B | ₩169B | — |
Kolon Life Science102940 · KOSDAQ | ₩12,660 | −1.86% | ₩818M | ₩166B | 0.50% |
Aptabio Therapeutics293780 · KOSDAQ | ₩5,790 | −7.21% | ₩741M | ₩163B | 0.05% |
Dongsung Pharmaceutical002210 · KOSPI | ₩1,221 | −5.28% | ₩54M | ₩118B | 0.00% |
ilShinbiobase068330 · KOSDAQ | ₩994 | +1.22% | ₩38M | ₩44B | — |
Aprogen Biologics003060 · KOSPI | ₩1,379 | −0.58% | ₩137M | ₩40B | 0.08% |
SeouLin Bioscience038070 · KOSDAQ | ₩3,595 | −2.18% | ₩40M | ₩33B | — |
Dt&Cro383930 · KOSDAQ | ₩2,095 | −2.33% | ₩118M | ₩27B | — |
C&R Research359090 · KOSDAQ | ₩2,205 | −1.78% | ₩15M | ₩25B | — |
Source: KRX statistical information